Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710756 · ClinicalTrials.gov registry record · Phase 1
Lead-212 PSV359 Therapy for Patients With Solid Tumors
A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Perspective Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
- 3
- Study locations
NCT06710756 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is actively recruiting participants, run by Perspective Therapeutics. The registered enrollment target is 112 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06710756, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Perspective Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Conditions Studied
Interventions
- DRUG [203Pb]Pb-PSV359
- DRUG [212Pb]Pb-PSV359
Study Locations (3)
Missouri
- Saint Louis University - St Louis
Nebraska
- Nebraska Cancer Specialists - Omaha
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2032-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06710756
The ClinicalTrials.gov registry entry for NCT06710756 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Perspective Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which [203Pb]Pb-PSV359 is the first listed.
NCT06710756 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Missouri, Nebraska, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06710756 about?
NCT06710756 is a clinical study titled "Lead-212 PSV359 Therapy for Patients With Solid Tumors". Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
What is the current status of trial NCT06710756?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2025-04-28. Estimated completion is 2032-05-28.
What conditions does trial NCT06710756 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT06710756?
The interventions under investigation include: [203Pb]Pb-PSV359 (DRUG), [212Pb]Pb-PSV359 (DRUG).
Who is sponsoring clinical trial NCT06710756?
This trial is sponsored by Perspective Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710756 being conducted?
This trial has 3 study locations across Missouri, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.